60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
DUBLIN - Morgan Stanley & Co. LLC disclosed Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) securities conducted on October 28, 2025, according to a regulatory filing with the Irish Takeover Panel.
The filing, made under Rule 38.5(a) of the Irish Takeover Panel Act, shows that Morgan Stanley, acting as an exempt principal trader with recognized intermediary status in a client-serving capacity, purchased 530,330 ordinary shares of Avadel Pharmaceuticals at prices ranging from $18.55 to $18.6076 per share.
The disclosure also revealed that Morgan Stanley sold 706,940 Avadel ordinary shares on the same day, within the identical price range of $18.55 to $18.6076 per share.
Morgan Stanley confirmed in the filing that it is connected to Avadel Pharmaceuticals in relation to the disclosed transactions. The firm stated there were no indemnity arrangements, agreements, or understandings relating to options or derivatives associated with these trades.
The disclosure was made in compliance with Irish takeover regulations requiring transparent reporting of dealings by connected exempt principal traders. According to the filing, no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were conducted during this period.
The information was provided through a Regulatory Information Service, as required by Rule 38 of the Irish Takeover Rules.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.